Skip to content

Lcr35 / ICU / P. Aeruginosa

Prevention of Gastric Colonisation by Antibiotic Resistant Pseudomonas Aeruginosa Strains Using Oral Probiotic in ICU-Patients

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00621803
Enrollment
400
Registered
2008-02-22
Start date
2003-03-31
Completion date
2005-10-31
Last updated
2008-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudomonas Infections

Keywords

Probiotic, Pseudomonas aeruginosa, Gastric colonization, Respiratory tract colonization, Ventilator aquired pneumoniae, determine the effect of oral administration of this probiotic on gastric and respiratory tract colonisation/infection by P. aeruginosa

Brief summary

Preventing carriage of potentially pathogenic micro-organisms from the aerodigestive tract is an infection control strategy used to reduce the occurrence of nosocomial infections - including ventilator-assisted pneumonia - in intensive care units. The use of antibiotics is controversial and can lead to adverse effect such as the selection of highly resistant pathogens. The purpose of this study was to investigate the effect of oral administration of a probiotic strain, Lactobacillus, on gastric and respiratory tract colonisation/infection by Pseudomonas aeruginosa strains, according to the concept that an indigenous flora has a protective effect against secondary colonisation.

Detailed description

In this prospective double-blind randomised study, ICU patients receive twice a day either an oral dose of Lactobacillus casei rhamnosus, the available pharmaceutical form, or a placebo. Digestive tract carriage of Pseudomonas aeruginosa is monitored by cultures of gastric aspirates. The occurrence of respiratory tract colonisations / infections is monitored throughout the study. Evaluation criteria are the delay and the rates of gastric P. aeruginosa colonisation and respiratory tract infection or colonisation. Chi-square or two tailed Fisher exact test are used for comparing qualitative variables and Student's t-test or mann-Whitney test for quantitatives variables. The mean of non-acquisition expectancy (NAE), length of stay without P. aeruginosa acquisition, was calculated and P. aeruginosa non-colonized patient rates were estimated and the two groups compared with regard to survival curves from grouped data using the Kaplan Meier method and the Logrank test. Variables with a P. value ≤0.15 in the univariate analysis were included in a logistic regression and a Cox regression model for multivariate analysis.

Interventions

DRUGProbiotic Lactobacillus casei rhamnosus (Lcr35)

Sponsors

Université d'Auvergne
CollaboratorOTHER
University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* more than 18 years old * length of stay longer than 48h * with a nasogastric feeding tube

Exclusion criteria

* \- less than 18 years old * length of stay \< 48h * immunosuppression * absolute neutrophile count \< 500/mm3 * gastro-intestinal bleeding * contraindicated enteral feeding * positive P. aeruginosa gastric aspirates or respiratory tract specimens during the first four days after hospital admission

Design outcomes

Primary

MeasureTime frame
Delay in P.aeruginosa colonisation

Secondary

MeasureTime frame
Delay of respiratory tract infection or colonisation due to P.aeruginosa. Persistance of L.casei rhamnosus in to the stomach

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026